Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

McMaster University

$85,000.00

The impact of supplementary prescription drug insurance and cost-sharing on drug use, health services utilization and health in Canada: a systematic review

FY 2016-17

Summary
Canada is widely cited as the only high-income country providing all residents with health insurance coverage for basic services, such as visits with physicians and hospital care, but lacking universal coverage for prescription drugs. Typically, Canadian provinces provide extended coverage including prescription drugs for specifically targeted population sub-groups (e.g., low-income individuals and families, elderly individuals and those on long-term disability). Residents not included in these population sub-groups either have no coverage and therefore must pay out-of-pocket for their prescription drugs or rely on supplementary drug insurance (e.g., provided by their employer, individually purchased). Scholars, clinicians, and advocacy groups across the country have made the case for extending public health insurance coverage to include prescription drugs for all residents (e.g. Advisory Panel on healthcare Innovation; Pharmacare 2020). While this issue has recently gained traction, momentum to implement a national pharmacare programme has historically been stymied by jurisdictional funding issues between federal and provincial governments. We seek to provide a comprehensive and systematic synthesis of evidence from both the international and Canadian contexts, to understand how current arrangements (such as cost-sharing schemes), and possible future expansion of benefits across Canada, may impact prescription drug use, health service use (e.g., physician visits to obtain a prescription), and ultimately the health outcomes of Canadians. We will draw upon literature from several disciplines - health economics, health services research, health policy, political science - to present comprehensive findings. Since each province has its own unique health system, its own health insurance plan and differing thresholds of eligibility, we will emphasize studies using Canadian data and highlight provincial differences to draw conclusions and policy implications.
Program
Project Grant
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
358603
Name
Guindon Godefroy E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Project Grant Competition
Projecttitle
The impact of supplementary prescription drug insurance and cost-sharing on drug use, health services utilization and health in Canada: a systematic review
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$85,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Cost-Sharing; Prescription Drug; Supplementary Insurance; Systematic Review
Abstract
Canada is widely cited as the only high-income country providing all residents with health insurance coverage for basic services, such as visits with physicians and hospital care, but lacking universal coverage for prescription drugs. Typically, Canadian provinces provide extended coverage including prescription drugs for specifically targeted population sub-groups (e.g., low-income individuals and families, elderly individuals and those on long-term disability). Residents not included in these population sub-groups either have no coverage and therefore must pay out-of-pocket for their prescription drugs or rely on supplementary drug insurance (e.g., provided by their employer, individually purchased). Scholars, clinicians, and advocacy groups across the country have made the case for extending public health insurance coverage to include prescription drugs for all residents (e.g. Advisory Panel on healthcare Innovation; Pharmacare 2020). While this issue has recently gained traction, momentum to implement a national pharmacare programme has historically been stymied by jurisdictional funding issues between federal and provincial governments. We seek to provide a comprehensive and systematic synthesis of evidence from both the international and Canadian contexts, to understand how current arrangements (such as cost-sharing schemes), and possible future expansion of benefits across Canada, may impact prescription drug use, health service use (e.g., physician visits to obtain a prescription), and ultimately the health outcomes of Canadians. We will draw upon literature from several disciplines - health economics, health services research, health policy, political science - to present comprehensive findings. Since each province has its own unique health system, its own health insurance plan and differing thresholds of eligibility, we will emphasize studies using Canadian data and highlight provincial differences to draw conclusions and policy implications.
Competitiondate
201610
Approvedterm2
1 yr 6 mths
Pinamesdelim
Guindon, Godefroy E; Hay, Carley; Sweetman, Lennox Arthur
Approvedterm
1 an 6 mois
Cihrcontribution2
~ $85,000~ $0~